Recurrent or Progressive High-Grade Glioma – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Recurrent or Progressive High-Grade Glioma Emerging Therapy and TPP Insights

Thelansis’s “Recurrent or Progressive High-Grade Glioma Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Recurrent or Progressive High-Grade Glioma Overview

Recurrent or progressive high-grade glioma is a malignant CNS tumor that returns or advances after prior treatment, with glioblastoma representing a major clinical challenge. Recurrence reflects infiltrative growth, molecular heterogeneity, treatment resistance, and an immunosuppressive tumor microenvironment. Management may include repeat surgery, reirradiation, systemic therapy, and clinical trials; bevacizumab is FDA-approved for progressive glioblastoma after prior therapy. No standard salvage approach reliably produces durable control. Development is exploring oncolytic viruses, local immune-engaging therapies, vaccines, CAR-T cells, and other cellular or gene-based platforms. Early studies demonstrate feasibility and antitumor activity, but responses are heterogeneous and durability remains limited. Major barriers include antigen heterogeneity, immune suppression, adaptive resistance, toxicity, CNS delivery, and limited tumor penetration. Priorities include biomarker-guided patient selection, rational combinations, and more durable disease control. Better delivery and durable immune control remain central goals.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)